Modulators of aldehyde dehydrogenase and methods of use thereof
The present disclosure provides compounds that function as modulators of aldehyde dehydrogenase (ALDH) enzymatic activity, as well as compositions and formulations comprising the compounds. The present disclosure provides therapeutic methods involving administering a subject compound, or a subject pharmaceutical composition.
1. A compound of Formula Ic:
wherein X n and X y are each independently H, C, N, O, or a halogen; where n is the integer 0 or 1; where y is the integer 0 or 1;
wherein (dotted line) is an optional bond;
wherein z is the integer 0, 1, or 2, with the provisos that: 1) z =0 when X =halogen and is not a bond; and 2) when z =0, X =O, is not a bond, and one or more oxygen atoms (X) are present, oxygen is attached to a methyl group;
where Ar is selected from a substituted phenyl and a substituted thiophene group; wherein the phenyl group is substituted with one or more C 1 to C 7 alkyl and an isoxazolyl group, and the thiophene group is substituted with C(O)NH 2 ;
or a pro-drug, a pharmaceutically acceptable salt, or a derivative thereof.
2. The compound of claim 1 , wherein X n and X y are both O.
3. The compound of claim 1 , wherein z is 1.
4. The compound of claim 1 , wherein Ar is a substituted phenyl.
5. The compound of claim 4 , wherein the phenyl is substituted with a methyl group.
6. The compound of claim 1 , wherein the isoxazolyl group is substituted with one or more methyl groups.
7. The compound of claim 1 , wherein Ar is a substituted thiophene group.
8. A compound having a structure selected from:
9. A pharmaceutical composition comprising:
a) a compound of claim 1 ; and
b) a pharmaceutically acceptable excipient.
10. A pharmaceutical composition comprising:
a) a compound of claim 8 ; and
b) a pharmaceutically acceptable excipient.
11. A method of reducing a level of aldehyde present at a toxic level in an individual to below the toxic level comprising administering to an individual an effective amount of a compound of claim 1 .
12. The method of claim 11 , wherein the individual has alcohol intolerance, alcohol addiction, or an alcohol abuse disorder.
13. A method of treating a disease or disorder selected from alcohol intolerance, alcohol addiction, alcohol abuse disorder, methanol poisoning, ethylene glycol monomethyl ether poisoning, and poisoning due to other xenogenic or biogenic aldehyde compounds, comprising administering to an individual an effective amount of a compound of claim 1 .
14. The method of claim 13 , wherein the disease or disorder is alcohol addiction.
15. The method of claim 13 , wherein the disease or disorder is alcohol intolerance.
16. The method of claim 13 , wherein the individual is heterozygous or homozygous for the ALDH2*2 allele.
17. The method of claim 13 , wherein the compound is administered parenterally or orally.
18. A method of detoxifying alcohol in an individual in need thereof, the method comprising administering to the individual an effective amount of a compound of claim 1 .
19. A pharmaceutical composition comprising:
a) a compound having the structure:
and
b) a pharmaceutically acceptable excipient.
20. A method of reducing a level of aldehyde present at a toxic level in an individual to below the toxic level comprising administering to an individual an effective amount of a pharmaceutical composition of claim 19 .
21. A method of treating a disease or disorder selected from alcohol intolerance, alcohol addiction, alcohol abuse disorder, methanol poisoning, ethylene glycol monomethyl ether poisoning, and poisoning due to other xenogenic or biogenic aldehyde compounds, comprising administering to an individual an effective amount of a pharmaceutical composition of claim 19 .